Dataset Information

Mapping of nascent RNA in MLL2 F/F and FC/FC MEF cells

ABSTRACT: Global Run-On has been performed in MLL2 F/F and FC/FC MEF cells. The aim of the experiment is to test how the lack of MLL2 affects nascent RNA transcription. Four samples were analyzed - 2 independent replicates. The experiments were performed using immortalized mouse embryonic fibroblasts (MEF) in which both MLL2 alleles were targeted by the loxp system (F/F cells). Tamoxifen treatment of the F/F cells for 24 hours results in the excision of both MLL2 alleles (FC/FC cells).

OTHER RELATED OMICS DATASETS IN: PRJNA296117PRJNA296116PRJNA296118

ORGANISM(S): Mus musculus

SUBMITTER: Theodoros Kantidakis Jesper Q Svejstrup Theo Kantidakis

PROVIDER: E-GEOD-73126 | ArrayExpress | 2016-04-13

SECONDARY ACCESSION(S): SRP063847GSE73126PRJNA296117

REPOSITORIES: GEO, ArrayExpress, ENA

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	E-GEOD-73126.idf.txt	Idf
	E-GEOD-73126.processed.1.zip	Processed
	E-GEOD-73126.sdrf.txt	Txt

Items per page:

1 - 3 of 3

Publications

Mutation of cancer driver MLL2 results in transcription stress and genome instability.

Kantidakis Theodoros T Kantidakis Theodoros T Saponaro Marco M Mitter Richard R Horswell Stuart S Kranz Andrea A Boeing Stefan S Aygün Ozan O Kelly Gavin P GP Matthews Nik N Stewart Aengus A Stewart A Francis AF Svejstrup Jesper Q JQ

Genes & development 20160201 4

Genome instability is a recurring feature of tumorigenesis. Mutation in MLL2, encoding a histone methyltransferase, is a driver in numerous different cancer types, but the mechanism is unclear. Here, we present evidence that MLL2 mutation results in genome instability. Mouse cells in which MLL2 gene deletion can be induced display elevated levels of sister chromatid exchange, gross chromosomal aberrations, 53BP1 foci, and micronuclei. Human MLL2 knockout cells are characterized by genome instabi ...[more]

PMID: 26883360

Similar Datasets

Project description:We used human or mouse MLL2-impaired cells (including a human DSET MLL2 cell line,) as well as their parental controls, and measured mutations in histones and a few other genes that were affected in our gH2AX ChIP-Seq experiments. We found that cells lacking or having impaired MLL2 were presenting statistically signifficant, higher levels of mutations at the tested genes as compared to their parental controls. The experiments were performed using human and mouse cells. For the human cells, the parental HCT116 cells were used as control. Two different MLL2 KO clones (KO19 and KO34) and a DSET MLL2 cell line were employed. For the mouse cells, the F/F cells were used, in which both MLL2 alleles are targeted by loxp. Tamoxifen treatment for 24 hours results in the excision of both MLL2 alleles (FC/FC cells). F/F cells were treated with tamoxifen (FC/FC) or vehicle (DMSO, F/F) for 24 hours. Half of the cells were then harvested and used as controls (T0), while the other half were cultured for another 30 days (T30). Mutations after 30 days (T30) of tamoxifen/vehicle treatment were measured compared to the T0 controls. In all cases, two different pools of primers were employed. All histone genes available to target with high coverage were studied, in either human or mouse cells. For the human cells, 32 histone (HIST1H1A HIST1H1B HIST1H1C HIST1H1D HIST1H1E HIST1H1T HIST1H2AC HIST1H2AD HIST1H2AG HIST1H2AH HIST1H2AI HIST1H2AJ HIST1H2AK HIST1H2BF HIST1H2BG HIST1H2BH HIST1H2BI HIST1H2BJ HIST1H2BK HIST1H2BN HIST1H3B HIST1H3C HIST1H3D HIST1H3E HIST1H3F HIST1H3G HIST1H3H HIST1H3I HIST1H4B HIST1H4F HIST1H4J HIST2H2AC) and 6 other genes (BTG2 SGK1 MDM2 CDKN1A EGR1 RPLP0) were targeted. For the mouse cells, 21 histone (HIST1H1A HIST1H1B HIST1H1C HIST1H1D HIST1H1E HIST1H1T HIST1H2AK HIST1H2BQ HIST1H3B HIST1H3C HIST1H3F HIST1H4F HIST1H4J HIST1H4N HIST1H4N HIST2H2AA1 HIST2H2AA1 HIST2H2AA2 HIST2H2AA2 HIST2H2AC HIST2H2BB) and 6 other genes (BTG2 SGK1 MDM2 CDKN1A EGR1 RPLP0) were targeted. Processed data to be submitted to appropriate variation archive.

Project description:Monoclonal antibody (mAb) immunotherapy has transformed the treatment of allergy, autoimmunity, and cancer. The interaction of mAb with Fc gamma receptors (Fc?R) is often critical for efficacy. The genes encoding the low-affinity Fc?R have single nucleotide polymorphisms (SNPs) and copy number variation that can impact IgG Fc:Fc?R interactions. Leukocyte-based in vitro assays remain one of the industry standards for determining mAb efficacy and predicting adverse responses in patients. Here we addressed the impact of Fc?R genetics on immune cell responses in these assays and investigated the importance of assay format. Fc?R genotyping of 271 healthy donors was performed using a Multiplex Ligation-Dependent Probe Amplification assay. Freeze-thawed/pre-cultured peripheral blood mononuclear cells (PBMCs) and whole blood samples from donors were stimulated with reagents spanning different mAb functional classes to evaluate the association of Fc?R genotypes with T-cell proliferation and cytokine release. Using freeze-thawed/pre-cultured PBMCs, agonistic T-cell-targeting mAb induced T-cell proliferation and the highest levels of cytokine release, with lower but measurable responses from mAb which directly require Fc?R-mediated cellular effects for function. Effects were consistent for individual donors over time, however, no significant associations with Fc?R genotypes were observed using this assay format. In contrast, significantly elevated IFN-? release was associated with the FCGR2A-131H/H genotype compared to FCGR2A-131R/R in whole blood stimulated with Campath (p ? 0.01) and IgG1 Fc hexamer (p ? 0.05). Donors homozygous for both the high affinity FCGR2A-131H and FCGR3A-158V alleles mounted stronger IFN-? responses to Campath (p ? 0.05) and IgG1 Fc Hexamer (p ? 0.05) compared to donors homozygous for the low affinity alleles. Analysis revealed significant reductions in the proportion of CD14hi monocytes, CD56dim NK cells (p ? 0.05) and Fc?RIIIa expression (p ? 0.05), in donor-matched freeze-thawed PBMC compared to whole blood samples, likely explaining the difference in association between Fc?R genotype and mAb-mediated cytokine release in the different assay formats. These findings highlight the significant impact of FCGR2A and FCGR3A SNPs on mAb function and the importance of using fresh whole blood assays when evaluating their association with mAb-mediated cytokine release in vitro. This knowledge can better inform on the utility of in vitro assays for the prediction of mAb therapy outcome in patients.